CHENG KONG

Dr. CHENG KONG


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2016 in Scientific Reports
Verified
Journal Article
Open access
CKCHENG KONG
CHENG KONG
XZXiang-Zhi Zhu
Xiang-Zhi Zhu
Tsair-Fwu LEETsair-Fwu LEE
Tsair-Fwu LEE
PFPing-Bo Feng
Ping-Bo Feng
JXJian-Hua Xu
Jian-Hua Xu
YZYi-Qin Zhang
Yi-Qin Zhang
We investigated the incidence of temporal lobe injury (TLI) in 132 nasopharyngeal carcinoma (NPC) patients who had undergone intensity-modulated radiotherapy (IMRT) in our hospital between March 2005 and November 2009; and identified significant dosimetric predictors of TLI development. Contrast-enhanced lesions or cysts in the temporal lobes, as detected by magnetic resonance imaging (MRI), were regarded as radiation-induced TLIs. We used the least absolute shrinkage and selection operator (LASSO) method to select Dmax(the maximum point dose) and the D1cc(the top dose delivered to a 1-mL volume) from 15 dose-volume-histogram-associated and four clinically relevant candidate factors; the Dmaxand the D1ccwere the most significant predictors of TLI development. We drew dose-response curves for Dmaxand D1cc. The tolerance dose (TD) for the 5% and 50% probabilities of TLI development were 69.0 ± 1.6 and 82.1 ± 2.4 Gy for Dmaxand 62.8 ± 2.2 and 80.9 ± 3.4 Gy for D1cc, respectively. The incidence of TLI in NPC patients after IMRT was higher than expected because the therapeutic window is narrow. High-quality longitudinal studies are needed to gain further insight into the complex spatiotemporal effects of non-uniform irradiation on TLI development in NPC patients.

7 March 2022 in Journal of Immunotherapy
Verified
Journal Article
Open access
LZLijun Zhao
Lijun Zhao
YLYang Li
Yang Li
NJNing Jiang
Ning Jiang
XSXue Song
Xue Song
JXJianhua Xu
Jianhua Xu
XHxia he
xia he
Some patients with cancer treated with programmed death 1 (PD-1) inhibitors experience immune-related severe adverse events (ir-SAEs), however, predictors are limited. The objective was to identify clinicopathologic features that may be associated with a higher ir-SAE risk. This was a nested case-control study. After screening a total of 832 PD-1 inhibitor-treated patients, we identified 42 ir-SAE cases. According to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0, ir-SAEs were defined as grade ≥3 toxic effects associated with immunotherapy. A total of 126 controls were matched. The crude and adjusted risks of ir-SAEs were estimated by odds ratio (ORs) and 95% CIs using multivariate logistic regression models. Baseline neutrophil-to-lymphocyte ratio (NLR) [per SD increment-adjusted (aOR): 1.16], lactate dehydrogenase (LDH) ≥245 U/L (aOR: 2.39), and antibiotic exposure (aOR: 4.39) were associated with a higher risk of ir-SAEs. When NLR was categorized in 3 groups, significantly higher risks of ir-SAEs (aOR: 4.95) were found in participants in group 3 (>6) than in those in group 1 (<3). Furthermore, NLR (per SD increment-adjusted hazard ratio:1.08) were also significantly associated with shorter overall survival (OS). Baseline LDH ≥245 U/L and antibiotic exposure were no significant association with OS. In conclusion, ir-SAEs were associated between baseline NLR, LDH ≥245 U/L and antibiotic exposure. Lower NLR was correlated with longer OS for cancer.

11 March 2023 in Current Problems in Cancer
Verified
Journal Article
Closed access
XSXue Song
Xue Song
LZLijun Zhao
Lijun Zhao
NJNing Jiang
Ning Jiang
NDNaixin Ding
Naixin Ding
DZDan Zong
Dan Zong
XZXiangzhi Zhu
Xiangzhi Zhu